Two clinical scenarios illustrated shared decision-making in practice: a 58-year-old woman with TP53 mutation, L858R, and asymptomatic brain metastases drew unanimous consensus for treatment ...
The panel discusses a 52-year-old patient with metastatic TNBC including lung lesions and previously treated stable brain metastases, presenting for first-line treatment recommendations. The panel ...
Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results